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Accepted 13 November 2018Background: Higher plasma ﬁbroblast growth factor 21 (FGF21) levels predict incident cardiovascular events in
type 2 diabetes patients. However, whether FGF21 levels predict cardiovascular events in statin-treated patients
in the general population is unknown.We investigatedwhether FGF21 levels predict major cardiovascular event
(MCVE) in the Treating to New Targets (TNT) trial participants.
Methods:After 8-week run-in on atorvastatin 10mg/day, 10,001 patients with stable coronary disease in the TNT
trial were randomized to 10 mg or 80 mg/day of atorvastatin for a median of 4.9 years. We analyzed data from
1996 patients with plasma FGF21 levels measured at randomization. Among them, 1835 patients had FGF21
measured one-year post-randomization.
Results:Higher ln-transformed FGF21 levels at randomization were associatedwith higher risk of incidentMCVE
(adjusted hazards ratio per SD increase = 1.18, P= 0.019). At 1-year post-randomization, FGF21 levels were
lower in patients randomized to receive 80mgversus 10mgatorvastatin (186.9 versus 207.5 pg/mL respectively,
P= 0.006). Higher ln-transformed FGF21 levels at 1-year post-randomization were also associated with higher
subsequent risk ofMCVEs (adjusted hazards ratio per SD increase=1.24, P=0.009).However, changes in FGF21
levels over 1-year were not related to subsequent MCVE risk. FGF21 levels had signiﬁcant incremental value in
net reclassiﬁcation improvement in MCVE risk prediction.
Conclusions: Higher plasma FGF21 levels are associated with higher CVD risk in statin-treated high-risk patients.
Higher dose atorvastatin is associatedwith a reduction in FGF21 levels. FGF21 provides incremental value in CVD
risk prediction in statin-treated patients.
© 2018 Elsevier Inc. All rights reserved.partate aminotransferase; BMI,
coronary heart disease; CVD,
tion rate; FFA, free fatty acids;
ipoprotein; HR, hazards ratio;
ar event; NAFLD, non-alcoholic
nt; T2D, type 2 diabetes; TNT,
tion Annual Scientiﬁc Sessions,
University of New SouthWales,1. Introduction
Fibroblast growth factor 21 (FGF21), which is mainly produced and
secreted by the liver [1,2], plays an important role in glucose and lipid
metabolism [3–5]. It has anti-inﬂammatory, anti-diabetic and hypolip-
idaemic effects in animal studies [1,2]. However, in clinical studies, cir-
culating FGF21 levels are often elevated in obesity, dyslipidemia,
insulin resistance, metabolic syndrome, type 2 diabetes (T2D), non-
alcoholic fatty liver disease and coronary artery disease, and has been
identiﬁed as a potential biomarker for the early detection of cardiomet-
abolic dysfunction [1,2]. Elevated FGF21 levels in this context may be
due to FGF21 resistance resulting from impaired FGF21 signaling or
compensatory responses to the underlying metabolic stress [1,2].
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ated with coronary heart disease (CHD) [6], carotid atherosclerosis [7],
and acute myocardial infarction [8]. In T2D patients, elevated FGF21
levels can predict the development of incident total cardiovascular dis-
ease (CVD) events [9]. However, it is unknown whether circulating
FGF21 levels can predict CVD events in statin-treated patients. This is
particularly important given that statins are widely used for CVD pre-
vention, and hepatic FGF21 expression is repressed in statin-treated
mice [10].
The Treating to New Targets (TNT) trial was a double-blind random-
ized controlled trial [11]. Brieﬂy, 10,001 patients with stable coronary
artery disease (CAD) and an low-density lipoprotein (LDL) cholesterol
level off-therapy of 3.4–6.5 mmol/L (130–250 mg/dL), decreasing to
b3.4mmol/L (130mg/dL) after an 8-week run-in period on atorvastatin
10 mg/day, were randomized to 10 mg or 80 mg/day of atorvastatin
with a median follow-up period of 4.9 years [11]. The mean LDL choles-
terol during follow-up was 2.6 mmol/L (101 mg/dL) in the 10 mg/day
group and 2.0 mmol/L (77mg/dL) in the 80mg/day group. The primary
endpoint of total major cardiovascular events (MCVEs) occurred in
10.9% of patients in the 10 mg group and 8.7% of patients in the 80 mg
group (hazards ratio [HR] 0.78, 95% CI 0.69–0.89, P b 0.001) [11].
In the present study, we asked whether plasma FGF21 levels at the
time of randomization (after the 8-week atorvastatin 10 mg run-in pe-
riod) predictMCVEs in participants from the TNT trial.We also assessed
the effect of higher dose of atorvastatin on plasma FGF21 levels at one
year after randomization, and whether plasma FGF21 levels at one
year predict subsequent risk of MCVEs. The underlying rationale of the
study is to provide an insight into whether FGF21 is a CVD risk bio-
marker in statin-treated patients.
2. Material and Methods
2.1. Study Population
The study design and results of the TNT trial have been published
[11]. Patients with stable CADwere randomized to two doses of atorva-
statin (either 10 or 80mgdaily). Participantswere recruited in 14 coun-
tries and randomization occurred between July 1998 and December
1999 [11]. The primary endpoint was MCVE, a composite of (i) CHD
death, (ii) nonfatal, non–procedure-related myocardial infarction, (iii)
resuscitated cardiac arrest, and (iv) fatal or nonfatal stroke. All patients
gave written informed consent. The study was approved by local re-
search ethics committees or institutional review boards at each center
and was performed in accordance with the Helsinki Declaration.
Among 10,001 patients, 9960 had blood samples available at the
timeof randomization. PlasmaFGF21 levelsweremeasured in a random
sub-sample of 2032 participants, in which informed consent was ob-
tained for measuring non-lipid biomarkers (in addition to that origi-
nally collected for the primary study).
2.2. FGF21 Level Measurement
Blood sampleswere collected in 10-mL EDTAVacutainer (BD, Frank-
lin Lakes, New Jersey) venous blood collection tubes using standard
phlebotomy practices. Immediately after collection, tubes were gently
inverted six times, and centrifuged at 2000×g (10min). Plasma samples
were transferred into 8-mL freezer vials, frozen (−70 °C), shipped on
dry ice, and thawed for biomarker analysis. FGF21 levels were measured
from stored plasma samples obtained at randomization (after the 8-week
atorvastatin 10 mg run-in period) and again one year after randomiza-
tion. FGF21 levels were measured using ELISA kits from the Antibody
and Immunoassay Services, University of Hong Kong, Hong Kong
(www.antibody.hku.hk) as described previously [9,12]. Brieﬂy 60 μL of
plasma sample was diluted 1:1 (v:v) with assay diluent and analyzed
together with quality controls as per the manufacturer's instruction.
The intra-assay and inter-assay CVs were b6%. All samples wereanalyzed masked for participant identity, treatment allocation and
time-point.
2.3. Statistical Analysis
Statistical analysis was performed using SPSS 24 (IBM, Armonk, NY)
or STATA 14.0 (StataCorp, College Station, TX). Data are presented as
mean ± SD or n (percentage). Comparisons of participant characteris-
tics at the time of randomization between treatment groups or out-
comes were performed using a chi-square test for categorical
variables, and an independent t-test for continuous variables. For non-
normally-distributed variables, data were presented as median (inter-
quartile range) and compared usingWilcoxon rank sum test. Treatment
allocation, age, sex, and other variables that showed a trend of differ-
ence (P b 0.1) in either treatment groupwere used as covariates in sub-
sequent multiple Cox regression analyses.
Associations of baseline FGF21 levels with incident MCVE over the
follow-up period was assessed using Cox proportional hazards regres-
sion analysis. In this analysis, for each participant that had an event,
the time to event (in days) was taken as that between the randomiza-
tion date and the date of the visit at which the earliest event was
ascertained. For participants who remained event-free, the follow-up
time was censored at last visit or last day known to be alive, whichever
was later. For subjects who died, follow-up time was censored at their
death date. As plasma FGF21 levels were highly skewed, data were ln-
transformed in the Cox regression analyses to prevent unstable esti-
mates of effects since extreme values may have undue inﬂuence on
the estimate of the regression coefﬁcient. Associations of FGF21 levels
and change in FGF21 levels at 1-year post-randomization with subse-
quently incident MCVE were analyzed similarly while excluding pa-
tients with any prior event (or censored) during the ﬁrst year post-
randomization. Survivals were estimated by the Kaplan-Meier method
and compared by the log-rank test. The proportional hazards assump-
tionwas checked using Schoenfeld residuals and no signiﬁcant violation
was found. In all analyses,we also investigatedwhether therewas an in-
teraction by treatment allocation. P for interaction was estimated by in-
cluding the interaction term in the regression models in the full sample
after adjustment for the main effects of the covariates. The incremental
value of the addition of ln-transformed FGF21 levels in the Cox regres-
sion model was assessed by the change in Harrell's C-statistic using a
method adapted for survival models [13]. The goodness of ﬁt of the
models was assessed using the Gronnesby and Borgan test [14]. Net
reclassiﬁcation improvement (NRI) were also assessed as described
previously [15]. As the NRI method is highly sensitive to the chosen
cut-points of risk and there are no pre-speciﬁed cut-points that can be
applied to the outcome appropriately, the category-free NRI (NRI N 0)
approach was utilized with both “event NRI” and “nonevent NRI” calcu-
lated [16]. NRI was calculated using a macro in SAS 9.4 (SAS Institute,
Cary, NC) [17]. A two-tailed P b 0.05 was considered statistically signif-
icant. In all the analyses, participants with missing data were excluded.
3. Results
3.1. Clinical Characteristics
As shown in Supplementary Table 1, therewere no signiﬁcant differ-
ence in age, sex, body mass index (BMI) and percentage of participants
receiving high-dose statin treatment between these 2032 participants
and the remaining 7928 participants (all P N 0.10). Among these
2032 participants, results from 36 participants (1.8%) were excluded
from further analysis as the FGF21 levels were below the assay limit of
detection (b8.69 pg/mL). Therefore, a total of 1996 participantswere in-
cluded in the analysis of plasma FGF21 levels at the time of randomiza-
tion. As shown in Supplementary Table 2, there were no signiﬁcant
difference in age, sex, BMI, percentage of participants receiving high-
dose statin treatment and other clinical characteristics between these
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cluded participants were more likely to be current smokers and had
higher total cholesterol than those not excluded (P= 0.039 and 0.031,
respectively).
Table 1 shows the clinical characteristics of the 1996 participants at
the time of randomization. Clinical characteristics were similar in the
groups randomized to remain on 10 mg atorvastatin (n = 1012,
50.7%) and to receive atorvastatin 80 mg (n= 984, 49.3%). Within the
same treatment group, participants who developed an MCVE were
more likely to be older, and have hypertension, diabetes and higher
white blood cell count at time of randomization, compared to partici-
pants who did not developed an MCVE. In the 10 mg atorvastatin
group, participants who developed an MCVE were also less likely to be
Caucasian, and more likely to be a current smoker, have lower high-
density lipoprotein (HDL) cholesterol and have higher triglyceride
levels than those who did not. In the 80 mg atorvastatin group, partici-
pants who developed an MCVE were also more likely to have a higher
BMI, and blood urea nitrogen levels.
3.2. FGF21 Levels at Randomization and Risk of MCVE
At randomization plasma FGF21 levels were signiﬁcantly higher in
participants with versus without incident MCVE (median [interquartile
range]: 253.5 [164.3–398.5] vs 204.6 [127.0–316.9] respectively, P b
0.001). Similar signiﬁcant differences was present within the 10 mg
and 80 mg atorvastatin group (Table 1). Fig. 1A shows the Kaplan-
Meier cumulative curves for incident MCVE over time across FGF21
level tertiles at randomization. Higher FGF21 tertiles at randomization
had a higher risk of incident MCVE (log-rank test P b 0.001). As shown
in Table 2, the association of ln-transformed FGF21 levels with incident
MCVE was signiﬁcant after adjusting for confounding variables, includ-
ing treatment allocation, age, sex, Caucasian race, BMI, smoking status,
hypertension, diabetes, HDL-cholesterol, triglycerides, blood urea nitro-
gen, and white blood cell count at baseline (P= 0.019). Similar signiﬁ-
cant results were obtained when continuous FGF21 levels were
assessed as a categorical tertile variable. No signiﬁcant treatment inter-
action was found. In a sensitivity analysis with exclusion of participants
with FGF21 levels in the top and bottom 5% (Supplementary Table 3),
higher FGF21 levels were still associated with higher risk of incident
MCVE after adjusting for confounding variables (P = 0.004 for ln-
transformed FGF21 levels and P= 0.020 for FGF21 tertiles).
3.3. Effect of High and Low Dose Atorvastatin on Plasma FGF21 Levels over
One Year
Among these 1996 participants, FGF21 levels were also measured at
one year after randomization in 1849 participants, of whom 14 partici-
pants (0.8%)were excluded from analysis due to FGF21 levels below the
assay limit. Therefore, a total of 1835 participants were included in the
analysis of FGF21 levels at one year. Table 3 shows the FGF21 levels at
randomization and 1-year post-randomization, as well as the absolute
and relative changes in FGF21 levels over one year by treatment groups
and status of incidentMCVE. At the time of randomization, therewas no
signiﬁcant difference in FGF21 levels between treatment groups (P =
0.83). However, at 1-year post-randomization, FGF21 levels in the
80 mg atorvastatin group, were signiﬁcantly lower than in the 10 mg
atorvastatin group (P = 0.006). FGF21 levels decreased more signiﬁ-
cantly over time in the 80mg atorvastatin group (P=0.001), compared
to the 10mgatorvastatin group (P=0.034),with both absolute and rel-
ative decreases in FGF21 levels being approximately twice that with
80 mg atorvastatin than with 10 mg atorvastatin (both P= 0.011). Al-
though, in both treatment groups, the FGF21 levels at randomization
and at 1-year post-randomization were signiﬁcantly higher in patients
with incident MCVE, compared to those without MCVE, the change in
FGF21 levels did not differ signiﬁcantly between participants with and
without incident MCVE in each treatment group.3.4. FGF21 Levels at One Year after Randomization and Subsequent Risk of
MCVE
Fig. 1B shows the Kaplan-Meier cumulative curves for incident
MCVE over time across FGF21 tertiles at 1-year post-randomization.
Participants in the higher FGF21 tertiles at 1-year post-randomization
had a higher subsequent risk of incident MCVE (log-rank test P b
0.001). As shown in Table 4, the association of ln-transformed FGF21
levels at one year with subsequent incident MCVE was signiﬁcant
after adjusting for confounding variables (P=0.009). Similar signiﬁcant
results were obtainedwhen continuous FGF21 levels were assessed as a
categorical tertile variable. No signiﬁcant treatment interaction was
found. However, when assessing the changes in FGF21 levels over 1-
year post-randomization as continuous variables, a larger relative
change in FGF21 levels was associated with higher subsequent risk of
MCVE (P = 0.002, Supplementary Table 4). However, such signiﬁcant
association was not found when assessing absolute changes in FGF21
level, or when assessing the changes as categorical variables (Supple-
mentary Fig. 1 and Supplementary Tables 4 & 5).
3.5. Incremental Value of FGF21 Levels for Risk Prediction
Addition of the FGF21 levels to a model adjusted for treatment allo-
cation, age, sex, Caucasian race, BMI, smoking status, hypertension, dia-
betes, HDL-cholesterol, triglycerides, blood urea nitrogen, and white
blood cell count only modestly increased the C-statistic, with a border-
line non-signiﬁcance P = 0.082 (Supplementary Table 6). When
assessing reclassiﬁcation using the category-free NRI(N0), addition of
FGF21 levels at randomization to a model with traditional cardiovascu-
lar risk factors signiﬁcantly increased the NRI(N0) of 20.9% for incident
MCVE (Table 5). This was the result of both correct upward reclassiﬁca-
tion of thosewith events (net gain in reclassiﬁcation of 16.4%), and from
correct downward reclassiﬁcation of nonevents (net gain in reclassiﬁca-
tion of 4.5%). Similar results were obtained when assessing the incre-
mental value of FGF21 levels at 1-year post-randomization.
4. Discussion
The present ﬁndings support FGF21 as a CVD biomarker in high risk
patients, even on statins. This is the ﬁrst study to investigate the associ-
ation of plasma FGF21 levels and CVD events in a clinical trial of statin-
treated subjects. Higher plasma FGF21 levels were associated with
higher CVD risk in statin-treated patients. Plasma FGF21 levels were
also decreased in the 80 mg atorvastatin group compared to the
10 mg atorvastatin group, but the changes in FGF21 levels over 1-year
post-randomization were not robustly related to subsequent CVD risk
over amedian of 3.9 years, it follows that statin-associated FGF21 reduc-
tion do not play a major role in statin-mediated CVD risk reduction.
The role of FGF21 in CVD has been reported in earlier pre-clinical
studies. Cardiomyocytes have been found to express and release
FGF21 in an autocrine-paracrine manner [18,19]. FGF21's anti-
inﬂammatory, anti-oxidative and anti-apoptotic properties of FGF21
also protect against CVD events, including cardiac hypertrophy and
myocardial infarction, in mice [18–21]. Global FGF21-knockout mice
are also more likely to develop cardiac hypertrophy than wild-type
mice [18].
Despite exhibiting cardioprotective effects in cell culture and pre-
clinical animal studies, elevated circulating FGF21 levels have been re-
ported in patients with CHD [22], carotid atherosclerosis [7,23], subclin-
ical atherosclerosis [24], and acute myocardial infarction [8]. These
observations could be due to the presence of FGF21 resistance in these
conditions. In rodent models, cardiomyocytes can secrete FGF21 in re-
sponse to global cardiac ischemia [19]. However, some human studies
have shown no associations between FGF21 levels and CVD [25,26].
Nevertheless, these studies are limited by having a cross-sectional de-
sign and relatively small sample size (n b 420).
Table 1
Clinical characteristics at time of randomization (n= 1996).
Clinical characteristics n Atorvastatin 10 mg Atorvastatin 80 mg P†
With MCVE Without MCVE P value⁎ With MCVE Without MCVE P value⁎
n 137 875 – 112 872 – –
Age, years 1996 63.3 (9.1) 60.8 (8.8) 0.003 63.4 (7.8) 61.2 (8.9) 0.006 0.53
Female, n (%) 1996 28 (20.4) 185 (21.1) 0.85 22 (19.6) 163 (18.7) 0.81 0.21
Caucasian race, n (%) 1996 117 (85.4) 814 (93.0) 0.002 106 (94.6) 795 (91.2) 0.21 0.73
Body mass index, kg/m2 1993 29.2 (5.1) 28.5 (4.7) 0.124 29.9 (5.7) 28.2 (4.3) 0.003 0.39
Smoking status, n (%) 1996 – – 0.035 – – 0.98 0.23
Current 26 (19.0) 98 (11.2) – 12 (10.7) 93 (10.7) – –
Former 84 (61.3) 581 (66.4) – 73 (65.2) 561 (64.3) – –
Hypertension, n (%) 1996 90 (65.7) 492 (56.2) 0.037 77 (68.8) 473 (54.2) 0.004 0.47
Systolic blood pressure, mmHg 1995 133.7 (16.7) 130.3 (15.9) 0.020 133.7 (17.8) 129.6 (17.1) 0.019 0.39
Diastolic blood pressure, mmHg 1995 76.5 (8.6) 77.2 (9.6) 0.40 77.3 (10.6) 76.8 (9.7) 0.59 0.55
Diabetes mellitus, n (%) 1996 34 (24.8) 112 (12.8) b0.001 28 (25.0) 125 (14.3) 0.003 0.48
Fasting glucose, mg/dL 1995 105 (95–127) 98 (90–110) b0.001 102 (93–116) 98 (91–111) 0.035 0.69
Total cholesterol, mg/dL 1995 175.6 (23.7) 174.0 (24.0) 0.48 176.8 (24.6) 173.7 (22.9) 0.17 0.85
LDL cholesterol, mg/dL 1994 98.7 (15.6) 96.9 (17.4) 0.25 98.4 (17.3) 96.5 (16.6) 0.27 0.62
HDL cholesterol, mg/dL 1995 44.4 (9.9) 47.5 (10.9) 0.002 47.2 (11.4) 47.9 (11.2) 0.57 0.14
Triglycerides, mg/dL 1995 150 (107–201) 133 (102–179) 0.028 137 (101–191) 133 (100–180) 0.25 0.45
Blood urea nitrogen, mg/dL 1996 16 (14–19) 16 (14–19) 0.49 17 (14–21) 16 (14–19) 0.022 0.45
White blood cell, 103/mm3 1996 6.5 (5.5–7.6) 6.1 (5.2–7.2) 0.007 6.5 (5.8–7.6) 6.1 (5.1–7.0) b0.001 0.17
ALT, U/L 1996 15 (12−21) 16 (12−20) 0.88 15 (12–20) 16 (12–20) 0.36 0.76
AST, U/L 1996 16 (13–19) 16 (13–19) 0.59 16 (13–19) 16 (13–19) 0.72 0.57
eGFR, mL/min/1.73 m2‡ 1996 62.2 (13.2) 64.1 (11.4) 0.11 62.7 (14.1) 64.3 (11.8) 0.25 0.65
FGF21, pg/mL 1996 258.9 (173.1–386.9) 205.4 (126.6–313.7) b0.001 241.2 (162.6–427.2) 203.1 (127.6–320.8) 0.005 0.59
Data are expressed as mean (SD), n (%), or median (interquartile range). Baseline characteristics at randomization were using a chi-square test for categorical variables, and a Wilcoxon
rank sum test or t-test for continuous variables, where appropriate.
Abbreviations: AST, Aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular ﬁltration rate; FGF21, ﬁbroblast growth factor 21; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; MCVE, major cardiovascular event.
⁎ P value for patients who experienced MCVE versus those who did not within each treatment group.
† P value for patients randomized to remain on 10 mg atorvastatin versus patients up-titrated to 80 mg atorvastatin.
‡ Calculated using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Fig. 1.Kaplan-Meier cumulative incidence curves forMCVEs across tertiles of FGF21 levels
at (A) randomization and (B) 1-year post-randomization. Abbreviations: FGF21, ﬁbroblast
growth factor 21; MCVE, major cardiovascular event.
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has been explored in earlier prospective studies. In a study of 87 T2D pa-
tients, above median FGF21 levels at baseline predicted higher CVmor-
bidity andmortality, but not totalmortality, over 2 years follow-up [27].
In another study of 1668 CAD patients, both lower and higher FGF21
levels predicted all-cause and CVD mortality over a median of
4.9 years follow-up, in which the smallest HR was associated with sec-
ond quartile of FGF21 levels [28]. In 253 Chinese subjects that
underwent a coronary angiography, serum FGF21 levels were indepen-
dently associated with prevalent CAD [6] and left ventricular systolic
dysfunction at baseline, and higher risk of cardiac death over 5 years
[29]. In the same cohort of subjects, higher serum FGF21 levels pre-
dicted development of major adverse cardiovascular events in 169 pa-
tients with CAD at baseline [30]. In another study of 3528 T2D
patients, the optimal cut-off value of serum FGF21 levels at baseline
was 206 pg/mL, levels above which predicted incident CHD over a me-
dian follow-up of 3.8 years [31]. In our previous study of 9697 T2D pa-
tients not on statin at baseline, higher plasma FGF21 levels predicted
CVD events over 5 years follow-up [9]. When considered together,
these results support FGF21 levels as a potential CVD biomarker, though
few participants were on statin therapy.
In the present study, higher plasma FGF21 levels at randomization
were associated with a higher risk of incident MCVE after adjusting for
confounding variables including demographics and traditional CVD
risk factors. Similar results were obtained with FGF21 levels assessed
as either a continuous or categorical (tertile) variable. Similar results
were obtained when subjects with FGF21 levels in the top or bottom
5% were excluded in the sensitivity analysis, or based on FGF21 levels
at 1-year post-randomization. This supports the robustness of our ﬁnd-
ings. The present larger study extends previous ﬁndings by showing
that plasma FGF21 levels can predict CVD events in high-CVD risk
statin-treated patients with stable CHD. Moreover, as no signiﬁcant
treatment interaction was found in all the analyses, it follows that the
association of FGF21 levels with MCVEs did not differ signiﬁcantly be-
tween low- and high-dose atorvastatin. This also suggests that FGF21-
Table 2
Association of FGF21 levels at randomization with risk of MCVEs (n = 1996).
Model n Outcome, n (%) All patients Atorvastatin 10 mg Atorvastatin 80 mg P for treatment interaction
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
ln-transformed FGF21⁎
Unadjusted model 1996 249 (12.5) 1.32 (1.17–1.49) b0.001 1.33 (1.14–1.57) b0.001 1.31 (1.10–1.57) 0.003 0.92
Adjusted model† 1992 247 (12.4) 1.18 (1.03–1.36) 0.019 1.19 (0.99–1.44) 0.062 1.13 (0.92–1.39) 0.25 0.93
FGF21 tertile
Unadjusted model 0.39
Tertile 1 (≤155.0 pg/mL) 665 55 (8.3) 1.00 (referent) – 1.00 (referent) – 1.00 (referent) –
Tertile 2 (155.1–280.9 pg/mL) 666 88 (13.2) 1.67 (1.19–2.34) 0.003 1.46 (0.92–2.32) 0.10 1.93 (1.17–3.17) 0.010 –
Tertile 3 (≥281.0 pg/mL) 665 106 (15.9) 2.10 (1.51–2.90) b0.001 2.22 (1.44–3.41) b0.001 1.95 (1.19–3.21) 0.008 –
Overall P value – b0.001 – 0.001 – 0.016 –
Adjusted model† 0.35
Tertile 1 (≤155.0 pg/mL) 664 54 (8.3) 1.00 (referent) – 1.00 (referent) – 1.00 (referent) –
Tertile 2 (155.1–280.9 pg/mL) 665 88 (13.2) 1.45 (1.03–2.05) 0.034 1.28 (0.80–2.06) 0.30 1.74 (1.05–2.89) 0.033 –
Tertile 3 (≥281.0 pg/mL) 663 105 (15.9) 1.56 (1.10–2.22) 0.013 1.71 (1.07–2.73) 0.025 1.37 (0.80–2.34) 0.25 –
Overall P value – 0.037 – 0.071 – 0.099 –
Abbreviations: FGF21, ﬁbroblast growth factor 21; HR, hazards ratio; MCVE, major cardiovascular event.
⁎ Data are expressed as HR (95% CI) in terms of per SD (0.8016) increase in ln-transformed levels.
† Data were adjusted for treatment allocation, age, sex, Caucasian race, body mass index, smoking status, hypertension, diabetes, high-density lipoprotein cholesterol, triglycerides,
blood urea nitrogen, and white blood cell count at baseline. Four patients (two with MCVE events) were excluded from adjusted model due to missing baseline body mass index for 3
subjects and missing baseline high-density lipoprotein cholesterol and triglycerides for 1 subject.
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which merits study. Statins are commonly used for CVD prevention. In
the present study, FGF21 levels decreased signiﬁcantly after 1-year of
atorvastatin, and the decreases in FGF21 levels were twice that with
high-dose atorvastatin than with low-dose atorvastatin. We speculate
this reduction could be due to reduced FGF21 resistance, but underlying
mechanisms of statin-associated reduction in FGF21 levels are not clear.
FGF21 is mainly produced and secreted by the liver. Notably, liver en-
zymes can be elevated by statins [32], in keeping with altered liver ho-
meostasis, which may affect FGF21 production. A recent meta-analysis
of controlled clinical trials has shown reduction of plasma free fatty
acids (FFAs) by atorvastatin [33], and FFAs can stimulate FGF21 expres-
sion in vitro [34]. Short-term simvastatin suppresses hepatic FGF21 ex-
pression and reduces circulating FGF21 levels in mice as well as FGF21
expression in mouse primary hepatocytes [10]. All these ﬁndings are
consistent with our clinical study results.
In this study, we also assessed the relationship of changes in FGF21
levels over 1-year post-randomization with subsequent risk of MCVEs
and found no robustly signiﬁcant associations. This suggests that
FGF21 may not play a major causal role in the development of MCVEs
over the short-term, even though its circulating levels can predict in fu-
ture MCVEs. However, it should be noted that the change in FGF21
levels found was small compared to the supraphysiological doses thatTable 3
FGF21 levels at randomization and 1-year post-randomization (n= 1835).
Parameter Atorvastatin 10 mg
All With MCVE Without MCVE P
v
n 946 120 826 –
FGF21, pg/ml
Time of
randomization
213.8
(132.7–328.0)
257.8
(156.5–387.8)
208.4
(129.8–318.2)
0
1-year
post-randomization
207.5
(127.2–330.1)
277.3
(154.9–383.4)
200.2
(122.7–313.5)
b
P for change⁎ 0.034 0.34 0.054 –
Change in FGF21 levels
Absolute change,
pg/mL
−10.8 (−78.8 to
60.1)
−13.7 (−100.8 to
82.0)
−9.4 (−75.8 to
57.7)
0
Relative change, % −4.7 (−34.3 to
37.3)
−3.5 (−38.1 to
38.8)
−4.8 (−34.0 to
37.3)
0
Data are expressed as median (interquartile range).
Abbreviations: FGF21, ﬁbroblast growth factor 21; MCVE, major cardiovascular event.
⁎ P value for the difference in FGF21 levels between time of randomization and 1-year post-
† P value for patients who experienced MCVEs versus those who did not in both treatment g
‡ P value for patients randomized to remain on 10 mg atorvastatin versus patients up-titratewere used in two proof-of-concept clinical trials of the FGF21 variants,
LY2405319 and PF-05231023 [35,36]. In those trials, treatment with
FGF21 variants improved body weight, lipid and adiponectin levels in
overweight/obese T2D patients [35,36]. Further studies are warranted
to investigate the effects of these FGF21 variants on CVD risk reduction.
Our study suggests FGF21 may be a CVD biomarker with potential
prognostic value as assessed by its ability to improve net reclassiﬁcation.
Although FGF21 levels did not result in a signiﬁcant change in the C-
statistic, the C-statistic is a less sensitive measure than the NRI(N0) ap-
proach [15]. Further studies are needed to compare the prognostic
value of FGF21 with other biomarkers, especially NT-proBNP, as well
as their prognostic ability with considered in combination.
The present study has several strengths. It takes advantage of the
large sample size, well-deﬁned inclusion and exclusion criteria, the
well-characterized double-blinded parallel study design and the uni-
form follow-up of the TNT trial, in which all patients took low-dose
atorvastatin for 8weeks pre-randomization. There are also some limita-
tions. Participants were not further stratiﬁed into subgroups based on
the number of coronary arteries involved or degree of stenosis, however
another cross-sectional study found no signiﬁcant difference in plasma
FGF21 levels among CHD patients by numbers of stenosed coronary ar-
teries involved [26]. The present study was a post-hoc analysis of the
TNT trial, though all analyses were performed after pre-statingAtorvastatin 80 mg P
value‡
alue†
All With MCVE Without MCVE P
value†
889 93 796 – –
.002 209.5
(134.1–325.7)
245.9
(164.6–398.5)
207.7
(132.3–323.8)
0.015 0.83
0.001 186.9
(114.9–301.9)
227.3
(138.1–365.9)
180.1
(114.6–295.9)
0.008 0.006
b0.001 0.34 b0.001 – –
.68 −19.6 (−96.0 to
40.2)
−13.2 (−97.7 to
61.7)
−20.8 (−95.4 to
40.0)
0.51 0.011
.87 −10.5 (−39.0 to
27.9)
−8.2 (−31.8 to
36.9)
−11.1 (−39.4 to
27.3)
0.27 0.011
randomization within each group using Wilcoxon signed rank test.
roups using Wilcoxon rank sum test.
d to 80 mg atorvastatin using Wilcoxon rank sum test.
Table 4
Association of FGF21 levels at 1-year post-randomization with subsequent risk of MCVE (n= 1801).
Model n Outcome, n
(%)
All patients Atorvastatin 10 mg Atorvastatin 80 mg P for treatment
interaction
HR (95% CI) P
value
HR (95% CI) P
value
HR (95% CI) P
value
ln-transformed FGF21 (per SD increase)*
Unadjusted model 1801 180 (10.0) 1.40 (1.22–1.61) b0.001 1.41 (1.17–1.71) b0.001 1.38 (1.12–1.69) 0.002 0.89
Adjusted model† 1797 178 (9.9) 1.24 (1.05–1.46) 0.009 1.27 (1.00–1.60) 0.046 1.17 (0.93–1.47) 0.19 0.99
FGF21 tertile
Unadjusted model 0.66
Tertile 1 (≤143.5 pg/mL) 600 39 (6.5) 1.00 (referent) – 1.00 (referent) – 1.00 (referent) –
Tertile 2 (143.6–265.5 pg/mL) 601 56 (9.3) 1.47 (0.98–2.22) 0.063 1.65 (0.91–3.00) 0.098 1.33 (0.75–2.34) 0.33 –
Tertile 3 (≥265.6 pg/mL) 600 85 (14.2) 2.33 (1.59–3.40) b0.001 2.78 (1.61–4.83) b0.001 1.92 (1.13–3.27) 0.017 –
Overall P value – b0.001 – b0.001 – 0.050 –
Adjusted model† 0.77
Tertile 1 (≤143.5 pg/mL) 599 38 (6.3) 1.00 (referent) – 1.00 (referent) – 1.00 (referent) –
Tertile 2 (143.6–265.5 pg/mL) 600 56 (9.3) 1.34 (0.88–2.04) 0.18 1.61 (0.87–2.99) 0.13 1.11 (0.62–1.99) 0.72 –
Tertile 3 (≥265.6 pg/mL) 598 84 (14.1) 1.70 (1.12–2.60) 0.013 2.07 (1.12–3.83) 0.021 1.31 (0.72–2.37) 0.38 –
Overall P value – 0.045 – 0.068 – 0.66 –
1835 patients had valid plasma FGF21 levels at 1-year post-randomization, but 34 patients with any prior event over year one were excluded from the analysis, resulting in a total sample
size of 1801 patients.
Abbreviations: FGF21, ﬁbroblast growth factor 21; HR, hazards ratio; MCVE, major cardiovascular event.
* Data are expressed as HR (95% CI) in terms of per SD (0.8045) increase in ln-transformed levels.
† Data were adjusted for treatment allocation, age, sex, Caucasian race, body mass index, smoking status, hypertension, diabetes, high-density lipoprotein cholesterol, triglycerides,
blood urea nitrogen, and white blood cell count at baseline. Four patients (two with MCVE events) were excluded from adjusted model due to missing baseline BMI for 3 subjects and
missing baseline high-density lipoprotein cholesterol and triglycerides for 1 subject.
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samples used for FGF21 measurement were stored at −80 °C for
N15 years, and we cannot exclude the possibility of confounding effects
due to long-term sample storage. However, in our previous pilot study,
serum FGF21 levels were stable after 1–6 freeze-thaw cycles a CV of
8.1% [12]. In an exploratory analysis, we did not ﬁnd any correlation be-
tween FGF21 levels and length of sample storage (Spearman correlation
coefﬁcient = 0.008, P = 0.72). During the FGF21 ELISA assay, not all
samples from the sameparticipantwere analyzed in the same analytical
run. However, the intra-assay and inter-assay CVs were small, and the
potential bias should be random in direction and weaken the observed
association.Table 5
Assessing the incremental value of ln-transformed FGF21 levels using the category-free
NRI (NRI N0) approach.
Outcome FGF21 at
randomization
FGF21 at 1-year
post-randomization
n 1992‡ 1797‡
NRI (N0) 0.2086 0.2071
SE 0.0621 0.0704
P value b0.001 0.003
Event NRI (N0)* 0.1635 0.1319
SE 0.0286 0.0329
P value b0.001 b0.001
Non-event NRI (N0)† 0.0451 0.0752
SE 0.0121 0.0126
P value b0.001 b0.001
Comparison are to bemade for the addition of FGF21 (ln-transformed) to amodel contain-
ing treatment allocation, age, sex, Caucasian race, bodymass index, smoking status, hyper-
tension, diabetes, high-density lipoprotein cholesterol, triglycerides, blood urea nitrogen,
and white blood cell count at baseline. The category-less NRI(N0) was calculated to quan-
tify the improvement gained due to correct upward or downward change in predicted
risks and is calculated as the proportion of event patients with correct upward or down-
ward change minus incorrect upward or downward change plus the corresponding pro-
portion among non-event patients. Values above zero for the NRI indicate improved risk
prediction and discrimination with the addition of FGF21 to the model.
Abbreviations: FGF21, ﬁbroblast growth factor 21; NRI, net reclassiﬁcation improvement.
⁎ Percentage correctly reclassiﬁed among subjects who had events.
† Percentage correctly reclassiﬁed among subjects who did not have events.
‡ Four patients (two with MCVE events) were excluded from adjusted model due to
missing baseline BMI for 3 subjects and missing baseline high-density lipoprotein choles-
terol and triglycerides for 1 subject.In summary, our TNT trial based study has demonstrated that
plasma FGF21 levels can predict incident MCVE over 5 years in statin-
treated patients with stable CHD. Our ﬁndings support the use of
FGF21 as a potential CVD risk biomarker in high-risk, statin-treated
patients.
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